Chikhoune Liticia, Poggi Claire, Moreau Julie, Dubucquoi Sylvain, Hachulla Eric, Collet Aurore, Launay David
CHU de Lille, Service de Médecine Interne et Immunologie Clinique, Centre de référence des Maladies Auto-Immunes et Auto-inflammatoires Systémiques rares de l'Adulte du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), 59000 Lille, France.
Institut d'Immunologie, Pôle de Biologie Pathologie Génétique Médicale, CHU de Lille, 59000 Lille, France; U1286-INFINITE-Institute for Translational Research in Inflammation, Université de Lille, 59000 Lille, France.
Rev Med Interne. 2025 Feb;46(2):89-106. doi: 10.1016/j.revmed.2024.10.452. Epub 2024 Nov 15.
Janus kinase (JAK) molecules are involved in important cellular activation pathways. Over the past decade, many targeted therapies have emerged, including the increasingly promising role of JAK inhibitors (JAKi) in the treatment of inflammatory and autoimmune diseases. The spectrum of use of these small molecules is increasingly broader. JAKi have been approved in several autoimmune diseases. Currently, four molecules (tofacitinib, baricitinib, upadacitinib and filgotinib) have been labeled for moderate to severe rheumatoid arthritis (RA) with failure or poor tolerance of one or more conventional disease-modifying antirheumatic drug (csDMARDS), or biologics (bDMARDS). JAKi are now also commonly used in other diseases such as psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. They have also shown promising results in clinical trials for the treatment of other autoimmune conditions. We present here their mechanisms of action, and the main data about JAKi use on systemic and autoimmune diseases.
Janus激酶（JAK）分子参与重要的细胞活化途径。在过去十年中，出现了许多靶向治疗方法，包括JAK抑制剂（JAKi）在治疗炎症性和自身免疫性疾病中日益显现的作用。这些小分子的应用范围越来越广。JAKi已在多种自身免疫性疾病中获得批准。目前，四种药物（托法替布、巴瑞替尼、乌帕替尼和非戈替尼）已被批准用于治疗对一种或多种传统改善病情抗风湿药物（csDMARDS）或生物制剂（bDMARDS）治疗失败或耐受性差的中度至重度类风湿性关节炎（RA）。JAKi现在也常用于其他疾病，如银屑病关节炎、强直性脊柱炎和溃疡性结肠炎。它们在治疗其他自身免疫性疾病的临床试验中也显示出了有前景的结果。我们在此介绍它们的作用机制，以及关于JAKi在全身性和自身免疫性疾病中应用的主要数据。
